Details for New Drug Application (NDA): 021285
✉ Email this page to a colleague
The generic ingredient in TRILEPTAL is oxcarbazepine. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
Summary for 021285
Tradename: | TRILEPTAL |
Applicant: | Novartis |
Ingredient: | oxcarbazepine |
Patents: | 0 |
Pharmacology for NDA: 021285
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 021285
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TRILEPTAL | oxcarbazepine | SUSPENSION;ORAL | 021285 | NDA | Novartis Pharmaceuticals Corporation | 0078-0357 | 0078-0357-52 | 250 mL in 1 BOTTLE (0078-0357-52) |
TRILEPTAL | oxcarbazepine | SUSPENSION;ORAL | 021285 | NDA AUTHORIZED GENERIC | Sandoz Inc | 0781-6270 | 0781-6270-43 | 250 mL in 1 BOTTLE (0781-6270-43) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 300MG/5ML | ||||
Approval Date: | May 25, 2001 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 021285
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | TRILEPTAL | oxcarbazepine | SUSPENSION;ORAL | 021285-001 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | TRILEPTAL | oxcarbazepine | SUSPENSION;ORAL | 021285-001 | May 25, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription